Lonza Group AG
/ Key word(s): AGMEGM
Basel, Switzerland, 8 May 2024 – Today, Lonza Group Ltd held its Annual General Meeting (AGM), led by the outgoing Chairman of the Board of Directors, Albert M. Baehny. 40.28% of the share capital was represented at the AGM, with attending and represented shareholders collectively holding a total of 29,994,055 shares. The Board members standing for re-election were all elected for a further term in office of one year. Those standing for re-election included Marion Helmes, Angelica Kohlmann, Christoph Mäder, Roger Nitsch, Barbara Richmond, Jürgen Steinemann and Olivier Verscheure. Jean-Marc Huët was elected to the Board of Directors and to the role of Chairman of the Board of Directors for a term of one year. He succeeds Albert M. Baehny, CEO ad interim, who will retire from Lonza in the summer as incoming CEO, Wolfgang Wienand, begins his tenure. The shareholders confirmed Angelica Kohlmann, Christoph Mäder and Jürgen Steinemann as the three members of the Compensation Committee for a further term in office of one year. The shareholders supported all other motions proposed by the Board of Directors, including the approval of the non-financial report, the remuneration report 2023 (consultative vote) and the binding votes on the compensation for the Board of Directors and the Executive Committee. Deloitte Ltd, Zurich (CH) was re-elected by shareholders as the auditor for the financial year 2025. A dividend of CHF 4.00 per share was proposed by the Board of Directors and approved by the shareholders. The payment period will commence from 15 May 2024. Fifty percent of this dividend will be paid out of the capital contribution reserves and will be exempt from Swiss withholding tax. For further information please see the detailed voting results. About Lonza Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 6.7 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2023. Find out more at www.lonza.com Lonza Contact Details Victoria Morgan Daniel Buchta Additional Information and Disclaimer Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes. Privacy Policy link
End of Media Release |
Language: | English |
Company: | Lonza Group AG |
Münchensteinerstrasse 38 | |
4052 Basel | |
Switzerland | |
Phone: | +4161 316 81 11 |
Internet: | www.lonza.com |
ISIN: | CH0013841017 |
Valor: | 1384101 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1898853 |
End of News | EQS News Service |
|
1898853 08.05.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.